Brief report: Endothelial progenitor cell phenotype and function are impaired in childhood-onset systemic lupus erythematosus

Arthritis and Rheumatology

Volumn 67, Issue 8, 2015, Pages 2257-2262

  Mohan, Smriti ^a   Barsalou, Julie ^b   Bradley, Timothy J ^b   Slorach, Cameron ^b   Reynolds, John A ^c   Hasni, Sarfaraz ^c   Thompson, Becky ^a   Ng, Lawrence ^b   Levy, Deborah ^b   Silverman, Earl ^b   Kaplan, Mariana J ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ADOLESCENT; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; HUMAN CELL; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; ONSET AGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR SURGERY; ANTAGONISTS AND INHIBITORS; ARTERIAL WALL THICKNESS; ARTHRITIS, JUVENILE; ASYMPTOMATIC DISEASE; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CYTOLOGY; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; PULSE WAVE; RISK FACTOR; VASODILATATION;

ADOLESCENT; ARTHRITIS, JUVENILE; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CHILD; CROSS-SECTIONAL STUDIES; ENDOTHELIAL PROGENITOR CELLS; FEMALE; HUMANS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PHENOTYPE; PULSE WAVE ANALYSIS; RISK FACTORS; VASODILATION;

EID: 84938068138     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39149     Document Type: Article

References (18)

1. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al., Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-7.
2. Kaplan MJ., Premature vascular damage in systemic lupus erythematosus. Autoimmunity 2009; 42: 580-6.
3. Stichweh D, Arce E, Pascual V., Update on pediatric systemic lupus erythematosus. Curr Opin Rheumatol 2004; 16: 577-87.
4. Urbina EM, Williams RV, Alpert BS, Collins RT, Daniels SR, Hayman L, et al., Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 2009; 54: 919-50.
5. Barsalou J, Bradley TJ, Silverman ED., Cardiovascular risk in pediatric-onset rheumatological diseases. Arthritis Res Ther 2013; 15: 212.
6. Ardoin SP, Schanberg LE, Sandborg CI, Barnhart HX, Evans GW, Yow E, et al., Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis 2014; 73: 557-66.
7. Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, et al., Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004; 103: 3677-83.
8. Denny M, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, et al., Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007; 110: 2907-15.
9. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak K, Banchereau J, et al., Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-23.
10. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al., Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.
11. Thacker S, Zhao W, Smith C, Luo W, Wang H, Vivekanandan-Giri A, et al., Type I interferons modulate endothelial function, repair, thrombosis and plaque severity in murine models of lupus and atherosclerosis. Arthritis Rheum 2012; 64: 2975-85.
12. Thacker S, Berthier C, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ., The detrimental effects of interferon-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunology 2010; 185: 4457-69.
13. Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram B, et al., Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 2012; 7: e37000.
14. Bruyndonckx L, Hoymans VY, Frederix G, De Guchtenaere A, Franckx H, Vissers DK, et al., Endothelial progenitor cells and endothelial microparticles are independent predictors of endothelial function. J Pediatr 2014; 165: 300-5.
15. Hortenhuber T, Rami-Mehar B, Satler M, Nagl K, Hobaus C, Hollerl F, et al., Endothelial progenitor cells are related to glycemic control in children with type 1 diabetes over time. Diabetes Care 2013; 36: 1647-53.
16. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
17. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al., Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25: 1991-4.
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.